BioXcel Therapeutics (NASDAQ:BTAI) announced Thursday it would no longer provide commercial support for its FDA-approved ...

Patients undergoing complex gastrointestinal malignancy surgeries experience various challenges such as immune system ...

BioXcel Therapeutics has announced a clinical reprioritization, focusing on late-stage development of its agitation treatment ...

Research on using sedation to improve patient tolerance to noninvasive ventilation (NIV) after traumatic chest injuries is ...

Reporting odds ratio (ROR), the proportional reporting ratio (PRR), and the Bayesian confidence propagation neural network (BCPNN) were employed to detect and assess adverse events associated with ...

Objectives: Although generally effective for sedation during noninvasive procedures, dexmedetomidine as the sole agent has not been uniformly successful for invasive procedures. To overcome some ...

The clinical prioritization is intended to optimize resource allocation and focus on the development of its lead neuroscience asset into potential new markets, while deprioritizing sales efforts for ...

BACKGROUND: Dexmedetomidine is an α 2-receptor agonist used for sedation in the intensive care unit (ICU). Although dexmedetomidine is labeled for sedation in critically ill patients at doses up ...

gmail.com Objectives To investigate the safety and effectiveness of dexmedetomidine for sedating patients in whom previous attempts at sedation in the emergency department have failed. Methods A study ...

Since traditional sedatives carry the risk of respiratory depression, this retrospective study was designed to compare sedation with the α 2 adrenergic agonist dexmedetomidine (DEX) and with GA for ...

Several meta-analyses have evaluated the antidelirium effects of dexmedetomidine in ICU patients, but their findings were inconsistent. Recently, several large multicentre randomised clinical trials ...